Biologics Seminar Series: Development of a vaccine against Chlamydia – A key role for adjuvants

The Biologics Seminar series is a programme of seminars organised by the Vaccine Design and Delivery group at the Department of Pharmacy. Each time, a different speaker is invited to present their work for one hour.


Dr. Frank Follmann, Director, Infectious Disease Immunology, Center for Vaccine Research, Statens Serum Institut, UCPH, will speak about Development of a vaccine against Chlamydia – A key role for adjuvants


There is a critical global need for a C. trachomatis vaccine to protect against human genital and ocular infections. Prevalence is increasing and current control measures have been widely unsuccesfull. Early efforts to develop a vaccine against ocular C. trachomatis infections were undertaken in the 1960’s, using pastuerian principles with whole cell vaccines. These trials were overall unsuccesfull but lessons learned are guiding research today. Experimentation in animal models together with information from clinical studies in humans have concluded that a vaccine will have to elicit strong Th1 cellular immune responses, with production of IFN-g and humoral responses that favour the generation of neutralizing antibodies. Therefore a key aspect of C. trachomatis vaccine reseach is the need to identify novel adjuvants and immunization schedules, that can elicit the desired immune response. Work has been restricted to preclinical testing for decades, but SSI recently completed the first clinical trial of a genital Chlamydia vaccine.  An overview of the development of the vaccine will be presented, with special focus on studies with adjuvants and novel vaccination schedules for the induction of mucosal immunity in the genital tract. 

Brief biography

Dr. Frank Follmann is the Director of Infectious Disease Immunology and Head of Chlamydia Vaccine Research at Statens Serum Institut. He is a Civil Engineer (Chemistry) by training and later acquired a PhD from the University of Copenhagen. From 2007 and onward, he has been leading a multidisciplinary team with the goal to develop a Chlamydia vaccine, a vaccine that was the first genital Chlamydia vaccine to reach clinical testing. Results were recently published in Lancet Infectious Diseases.

The seminar will last for 45 min + 15 min questions, and is free of charge. Please contact Prof. Camilla Foged​ for further information.